These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 18486285)

  • 41. Pulmonary vaccine delivery: a realistic approach?
    Tonnis WF; Kersten GF; Frijlink HW; Hinrichs WL; de Boer AH; Amorij JP
    J Aerosol Med Pulm Drug Deliv; 2012 Oct; 25(5):249-60. PubMed ID: 22856876
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer.
    Jo YM; Song JY; Hwang IS; Lee J; Oh SC; Kim JS; Kim SR; Kim WJ; Cheong HJ
    J Med Virol; 2009 Apr; 81(4):722-7. PubMed ID: 19235853
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chitosan-based systems for the delivery of vaccine antigens.
    Arca HC; Günbeyaz M; Senel S
    Expert Rev Vaccines; 2009 Jul; 8(7):937-53. PubMed ID: 19538118
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunogenicity and efficacy of intradermal tattoo immunization with adenoviral vector vaccines.
    Potthoff A; Schwannecke S; Nabi G; Hoffmann D; Grunwald T; Wildner O; Brockmeyer NH; Uberla K; Tenbusch M
    Vaccine; 2009 May; 27(21):2768-74. PubMed ID: 19366575
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vaccine delivery systems.
    Haensler J
    Vet Res; 1995; 26(3):226-31. PubMed ID: 7795687
    [No Abstract]   [Full Text] [Related]  

  • 46. Oil-in-water liposomal emulsions for vaccine delivery.
    Matyas GR; Muderhwa JM; Alving CR
    Methods Enzymol; 2003; 373():34-50. PubMed ID: 14714395
    [No Abstract]   [Full Text] [Related]  

  • 47. The nature and consequences of intra- and inter-vaccine interference.
    Vidor E
    J Comp Pathol; 2007 Jul; 137 Suppl 1():S62-6. PubMed ID: 17560593
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Heterologous prime-boost vaccinations for poverty-related diseases: advantages and future prospects.
    Radosević K; Rodriguez A; Lemckert A; Goudsmit J
    Expert Rev Vaccines; 2009 May; 8(5):577-92. PubMed ID: 19397415
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS.
    ;
    Expert Rev Vaccines; 2009 Jun; 8(6):705-16. PubMed ID: 19485752
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Attitudes of nurses toward current and proposed vaccines for public programs: a questionnaire survey.
    Gilca V; Boulianne N; Dubé E; Sauvageau C; Ouakki M
    Int J Nurs Stud; 2009 Sep; 46(9):1219-35. PubMed ID: 19349047
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reduced dose pre-exposure primary and booster intradermal rabies vaccination with a purified chick embryo cell vaccine (PCECV) is immunogenic and safe in adults.
    Roukens AH; Vossen AC; van Dissel JT; Visser LG
    Vaccine; 2008 Jun; 26(27-28):3438-42. PubMed ID: 18511158
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cutaneous delivery of prophylactic and therapeutic vaccines: historical perspective and future outlook.
    Mikszta JA; Laurent PE
    Expert Rev Vaccines; 2008 Nov; 7(9):1329-39. PubMed ID: 18980537
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Intradermal administration of a strong vaccine].
    Hennemann A
    Med Monatsschr Pharm; 2005 Oct; 28(10):362. PubMed ID: 16245452
    [No Abstract]   [Full Text] [Related]  

  • 54. Biomaterials as vaccine adjuvants.
    Jones KS
    Biotechnol Prog; 2008; 24(4):807-14. PubMed ID: 19194892
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Needle-free injection technology.
    Expert Rev Med Devices; 2006 Jan; 3(1):17-8. PubMed ID: 16359248
    [No Abstract]   [Full Text] [Related]  

  • 56. Vaccine injection technique and reactogenicity--evidence for practice.
    Petousis-Harris H
    Vaccine; 2008 Nov; 26(50):6299-304. PubMed ID: 18804137
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intradermal influenza vaccination in immunocompromized patients is immunogenic and feasible.
    Gelinck LB; van den Bemt BJ; Marijt WA; van der Bijl AE; Visser LG; Cats HA; Rimmelzwaan GF; Kroon FP
    Vaccine; 2009 Apr; 27(18):2469-74. PubMed ID: 19368788
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Research and development strategies, examples among new vaccines].
    Denis F; Ploy MC
    Ann Pharm Fr; 2009 May; 67(3):198-202. PubMed ID: 19446670
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Needle length and injection technique for efficient intramuscular vaccine delivery.
    Aggarwal A
    Indian Pediatr; 1998 Apr; 35(4):389-91. PubMed ID: 9770904
    [No Abstract]   [Full Text] [Related]  

  • 60. Reduced intradermal test dose of yellow fever vaccine induces protective immunity in individuals with egg allergy.
    Roukens AH; Vossen AC; van Dissel JT; Visser LG
    Vaccine; 2009 Apr; 27(18):2408-9. PubMed ID: 19368780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.